Skip to content
Research Article Open access CC BY 4.0

Evaluation of Liver Fibrosis by FibroScan in β-Thalassemia Children Infected with Hepatitis C Virus Before and After Ledipasvir/Sofosbuvir Therapy

Aya Lotfy Yosef, Hanan Hamed Soliman, Gamal El-Sayed Shiha, Mohiee El-Deen AbdEl-Aziz Awad, Eslam El-Sayed El-Hawary

International Blood Research & Reviews · pp. 9–17 · Published 27 Aug 2020

10.9734/ibrr/2020/v11i330130

Abstract

Background: Thalassemic children develop liver fibrosis because of liver iron overload and hepatitis C virus (HCV) infection. Transient elastography (FibroScan) can be a reliable non-invasive method for evaluating liver fibrosis in thalassemic patients. Treatment with ledipasvir/sofosbuvir (LED/SOF) direct acting antiviral agents can significantly affect liver stiffness measurement (LSM) by FibroScan. Aims: To assess liver fibrosis by non-invasive FibroScan through LSM before and after generic LED/SOF therapy in multi-transfused β-thalassemic children infected with HCV. Place and Duration of Study: Pediatric Hematology Unit, Tanta University Hospital, from November 2017 to May 2019. Methodology: Fifty multi-transfused β-thalassemic treatment-naϊve children (aged 12-18 years and weighing ≥35kg) with chronic HCV infection were subjected to clinical evaluation, quantitative HCV PCR assay, FibroScan examination, and calculation of APRI, FIB4 index and AST/ ALT ratio. In addition to standard therapy, generic LED/SOF (90/400 mg) treatment was given for 12 weeks’ duration with follow up for further 12 weeks after end of treatment. Results: A positive HCV PCR was changed into negative for all studied patients starting from week 4 after treatment. There was highly significant reduction in the LSM values by FibroScan in the studied patients after therapy (p-value <0.001) with median reduction of 19.4 %. The significant reduction in LSM values was particularly prominent in patients with significant (F2) and advanced (F3) liver fibrosis stages as well as cirrhotic patients (F4). There was significant reduction in the values of other non-invasive liver fibrosis markers FIB-4 index, APRI score and AST/ ALT ratio (p-value <0.001, <0.001 and 0.020 respectively) after therapy. Conclusion: Generic LED/SOF therapy for 12 weeks’ duration resulted in eradication of HCV infection that was associated with significant decrease in LSM by FibroScan particularly those with higher baseline liver fibrosis stages.

FibroScan liver fibrosis liver stiffness measurement β-Thalassemia Hepatitis C virus direct acting antiviral drugs ledipasvir/sofosbuvir

References (20)

  1. 1 Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ [DOI]
  2. 2 Transient elastography: a new noninvasive method for assessment of hepatic fibrosis [DOI]
  3. 3 Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C [DOI]
  4. 4 Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study [DOI]
  5. 5 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy [DOI]
  6. 6 Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial [DOI]
  7. 7 Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients [DOI]
  8. 8 Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index [DOI]
  9. 9 Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis [DOI]
  10. 10 Improvement of liver stiffness in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response [DOI]
  11. 11 Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon [DOI]
  12. 12 NONINVASIVE ASSESSMENT OF LIVER FIBROSIS WITH THE ASPARTATE TRANSAMINASE TO PLATELET RATIO INDEX (APRI): USEFULNESS IN PATIENTS WITH CHRONIC LIVER DISEASE
  13. 13 Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) – lack of interference by iron deposition [DOI]
  14. 14 Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications [DOI]
  15. 15 Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection [DOI]
  16. 16 The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C [DOI]
  17. 17 Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major [DOI]
  18. 18 Non-invasive Assessment of Liver Fibrosis Using Serum Markers
  19. 19 Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries [DOI]
  20. 20 Rapid detection of multiple β-globin gene mutations by a real-time polymerase chain reaction in β-thalassemia carriers [DOI]

Cited by 2

Evaluation of hepatic fibrosis by transient elastography in βthalassemia children before and after hematopoietic stem cell transplantation

Reem Salama, Eslam Elhawary, Dina Ziada · The Egyptian Journal of Haematology · 2023

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

53

Page views

0

PDF downloads

5

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.